Here are the DEF 14A proxy statements from Kiniksa Pharmaceuticals International, plc (KNSA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow KNSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KNSA filings page.
Kiniksa Pharmaceuticals International, plc is asking shareholders to vote on eight proposals at its 2026 Annual Meeting on May 29, 2026 at its London offices. Holders of Class A ordinary shares have one vote per share and Class B ordinary shares have ten votes per share as of the April 6, 2026 record date.
Proposals include re-electing three Class II directors until the 2029 meeting, appointing and ratifying PricewaterhouseCoopers LLP as UK statutory auditors and US independent registered public accounting firm, authorizing the Audit Committee to set PwC’s UK audit fees, and receiving the UK statutory annual report for 2025.
Shareholders are also being asked to approve, on an advisory basis, the UK Statutory Directors’ Remuneration Report, approve an updated UK Remuneration Policy governing director pay for up to three years, and cast a non-binding Say-on-Pay vote on compensation for named executive officers.